Dextromethorphan-Bupropion Delays Relapse of Alzheimer Disease Agitation
AXS-05 is an investigational agent consisting of a proprietary formulation of dextromethorphan and bupropion.
AXS-05 is an investigational agent consisting of a proprietary formulation of dextromethorphan and bupropion.
Gantenerumab is an investigational immunoglobulin G1 antibody designed to increase the clearance of soluble amyloid beta from the brain.
Stay up-to-date on the latest drugs in development.
Stay up-to-date on the latest drugs in development.
Lecanemab is an investigational anti-amyloid beta protofibril antibody.
Most neurological disorders do not appear to be more frequent after COVID-19 than after influenza or bacterial pneumonia
Crenezumab is an investigational monoclonal antibody designed to neutralize neurotoxic oligomers, a form of beta-amyloid.
The long-term extension phase of the phase 3 EMERGE and ENGAGE trials evaluated the efficacy and safety of aducanumab-avwa in adults aged 50 to 85 years with early Alzheimer disease.
Adlarity is a once-weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion.